Irish Journal of Medical Science (1971 -)

, Volume 186, Issue 3, pp 733–741 | Cite as

Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014

  • P. J. Stapleton
  • D. J. Lundon
  • R. McWade
  • N. Scanlon
  • M. M. Hannan
  • F. O’Kelly
  • M. Lynch
Original Article



Escherichia coli is a common cause of urinary tract infections (UTI). Reviews of antibiotic resistance of this organism can inform choice of empiric treatment of UTI and other infections and strategies for combating antimicrobial resistance. We reviewed laboratory and hospital pharmacy records to assess trends in non-susceptibility rates and the effect of antimicrobial stewardship interventions.


A retrospective observational study of isolates of E. coli from MSU samples at a Dublin teaching hospital from inpatients and community, obtained from January 2005 to December 2014. Susceptibility to a panel of antibiotics was determined using the disc diffusion method, as well as extended-spectrum beta-lactamase (ESBL) production status. Trends in resistance were plotted graphically and analysed in a descriptive manner.


Except for nitrofurantoin and gentamicin, non-susceptibility increased for all antimicrobials tested. Co-amoxiclav non-susceptibility reached 48% in hospital and 32.6% in the community by 2014. Piperacillin–tazobactam non-susceptibility increased from 6.8 to 23.8% in hospital and from <1 to 12.5% in community, with similar increases for ESBL producing isolates. Ciprofloxacin non-susceptibility peaked at 25.5% in hospital in 2012 and 11.44% in the community in 2014.


Escherichia coli isolates from community MSU samples have high rates of non-susceptibility to trimethoprim and co-amoxiclav. Nitrofurantoin remains the best empiric therapy for cystitis. Increasing non-susceptibility to co-amoxiclav and piperacillin–tazobactam in hospital isolates is concerning. Ciprofloxacin non-susceptibility is increasing faster in the community than in hospital. A sharp reduction in hospital fluoroquinolone consumption did not result in a significant reduction in ciprofloxacin non-susceptibility of hospital E. coli isolates.


Antibiotic resistance Antibiotic consumption E. coli Epidemiology 


Compliance with ethical standards

Conflicts of interest

DL: No conflicts of interest to declare. PS: No conflict of interest to declare. RW: No conflict of interest to declare. NS: No conflict of interest to declare. MH: No conflict of interest to declare. FO’K: No conflict of interest to declare. ML: No conflict of interest to declare.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

For this type of study, formal consent is not required.


  1. 1.
    Kaper JB, Nataro JP, Mobley HL (2004) Pathogenic Escherichia coli. Nat Rev Microbiol 2:123–140. doi: 10.1038/nrmicro818 CrossRefPubMedGoogle Scholar
  2. 2.
    European Centre for Disease Prevention and Control, Antimicrobial resistance surveillance in Europe (2012) Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Contro, StockholmGoogle Scholar
  3. 3.
    Bajaj P, Singh NS, Virdi JS (2016) Escherichia coli β-lactamases: what really matters. Front Microbiol 7:417. doi: 10.3389/fmicb.2016.00417 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Mathers AJ, Peirano G, Pitout JDD (2015) Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone. Adv Appl Microbiol 90:109–154. doi: 10.1016/bs.aambs.2014.09.002 CrossRefPubMedGoogle Scholar
  5. 5.
    Nathwani D, Sneddon J, Malcolm W et al (2011) Scottish Antimicrobial Prescribing Group (SAPG): development and impact of the Scottish National Antimicrobial Stewardship Programme. Int J Antimicrob Agents 38:16–26. doi: 10.1016/j.ijantimicag.2011.02.005 CrossRefPubMedGoogle Scholar
  6. 6.
    Lawes T, Lopez-Lozano J-M, Nebot CA et al (2015) Effects of national antibiotic stewardship and infection control strategies on hospital-associated and community-associated meticillin-resistant Staphylococcus aureus infections across a region of Scotland: a non-linear time-series study. Lancet Infect Dis 15:1438–1449. doi: 10.1016/S1473-3099(15)00315-1 CrossRefPubMedGoogle Scholar
  7. 7.
    Naughton C, Hennessy Y, Mannion C, Philbin M (2011) A comparison of antibiotic point prevalence survey data from four Irish regional/general hospitals. Ir J Med Sci 180:457–461. doi: 10.1007/s11845-011-0677-5 CrossRefPubMedGoogle Scholar
  8. 8.
    Livermore DM, Hope R, Reynolds R et al (2013) Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change? J Antimicrob Chemother 68:2667–2674. doi: 10.1093/jac/dkt212 CrossRefPubMedGoogle Scholar
  9. 9.
    CLSI (2012) Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard–Eleventh Edition. CLSI Document M02–A11. Clinical and Laboratory Standards Institute, WayneGoogle Scholar
  10. 10.
    CLSI (2012) Performance Standard for Antimicrobial Disk Susceptibility Testing. Twenty-Second Informational supplement. CLSI document No. M100-S2 CLSI. Clinical and Laboratory Standards InstituteGoogle Scholar
  11. 11.
    Grignon O, Montassier E, Corvec S et al (2015) Escherichia coli antibiotic resistance in emergency departments. Do local resistance rates matter? Eur J Clin Microbiol Infect Dis 34:571–577. doi: 10.1007/s10096-014-2264-y CrossRefPubMedGoogle Scholar
  12. 12.
    O'Neill J. Review on antimicrobial resistance. December 2014.
  13. 13.
    Chulain MN, Murray A-M, Corbett-Feeney G, Cormican M (2004) Antimicrobial resistance in E. coli associated with urinary tract infection in the west of Ireland. Ir J Med Sci 174(4):6–9CrossRefGoogle Scholar
  14. 14.
    Gupta K, Hooton TM, Naber KG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103–e120. doi: 10.1093/cid/ciq257 CrossRefPubMedGoogle Scholar
  15. 15.
    Totsika M, Beatson SA, Sarkar S et al (2011) Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS One 6:e26578. doi: 10.1371/journal.pone.0026578 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cullen IM, Manecksha RP, McCullagh E et al (2013) An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009. Ir J Med Sci 182:81–89. doi: 10.1007/s11845-012-0834-5 CrossRefPubMedGoogle Scholar
  17. 17.
    Vellinga A, Galvin S, Duane S et al (2016) Intervention to improve the quality of antimicrobial prescribing for urinary tract infection: a cluster randomized trial. CMAJ 188:108–115. doi: 10.1503/cmaj.150601 CrossRefPubMedGoogle Scholar
  18. 18.
    Tandan M, Duane S, Cormican M et al (2016) Reconsultation and antimicrobial treatment of urinary tract infection in male and female patients in general practice. Antibiotics 5:31. doi: 10.3390/antibiotics5030031 CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Sundqvist M, Geli P, Andersson DI et al (2010) Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use. J Antimicrob Chemother 65:350–360. doi: 10.1093/jac/dkp387 CrossRefPubMedGoogle Scholar
  20. 20.
    Vellinga A, Murphy AW, Hanahoe B et al (2010) A multilevel analysis of trimethoprim and ciprofloxacin prescribing and resistance of uropathogenic Escherichia coli in general practice. J Antimicrob Chemother 65:1514–1520. doi: 10.1093/jac/dkq149 CrossRefPubMedGoogle Scholar
  21. 21.
    Cullen IM, Manecksha RP, McCullagh E et al (2012) The changing pattern of antimicrobial resistance within 42°033 Escherichia coli isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999–2009. BJU Int 109:1198–1206. doi: 10.1111/j.1464-410X.2011.10528.x CrossRefPubMedGoogle Scholar
  22. 22.
    Ironmonger D, Edeghere O, Bains A et al (2015) Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years. J Antimicrob Chemother 70:1744–1750. doi: 10.1093/jac/dkv043 PubMedGoogle Scholar
  23. 23.
    Badura A, Feierl G, Pregartner G et al (2015) Antibiotic resistance patterns of more than 120,000 clinical Escherichia coli isolates in Southeast Austria, 1998–2013. Clin Microbiol Infect 21:569.e-1. doi: 10.1016/j.cmi.2015.02.012 CrossRefGoogle Scholar
  24. 24.
    Health Protection and Surveillance Centre (2014) European Antimicrobial Resistance Surveillance Network (EARS-Net) Report Quarters 1–4.,14686,en.pdf. Accessed 12 Oct 2015
  25. 25.
    Livermore DM, Ashiru-Oredope D, Sharland M et al (2014) Of stewardship, motherhood and apple pie. Int J Antimicrob Agents 43:319–322. doi: 10.1016/j.ijantimicag.2014.01.011 CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2017

Authors and Affiliations

  • P. J. Stapleton
    • 1
  • D. J. Lundon
    • 2
  • R. McWade
    • 1
  • N. Scanlon
    • 3
  • M. M. Hannan
    • 1
  • F. O’Kelly
    • 2
  • M. Lynch
    • 1
  1. 1.Department of Clinical MicrobiologyMater Misericordiae University HospitalDublinIreland
  2. 2.Department of Urology and Reconstructive SurgeryMater Misericordiae University HospitalDublinIreland
  3. 3.Department of PharmacyMater Misericordiae University HospitalDublinIreland

Personalised recommendations